The appointment of Matthew Farrelly as the next director of the Office of Science at the US Food and Drug Administration (FDA)’s Center for Tobacco Products (CTP) comes at a potentially critical time for tobacco alternatives in the US, with a number of big calls for the agency to make, including the next step in its ongoing attempt to regulate Juul e-cigarettes.
Farrelly, an expert in tobacco control research, will take up the post on 26th March, tasked by the FDA with a key role in “the centre’s critical mission to protect Americans from tobacco-related disease and death”.